

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### Evaluation of the effects of rice bran powder administration on cardiovascular risk factors in adult patients with metabolic syndrome: A Randomized Controlled Open Label Trial

#### Protocol summary

##### Study aim

Determining the effects of rice bran powder on cardiovascular risk factors in adult patients with metabolic syndrome

##### Design

Clinical trial with control group, with parallel groups, without blinding, randomized, phase 2 on 50 patients to allocate consumption to the subjects will use the randomized block method. The website <http://www.randomization.com> will also be used for randomization.

##### Settings and conduct

Fifty patients with metabolic syndrome referred to the outpatient clinic of Dr. Heshmat Heart Training Center will be admitted to the study with personal consent after completing the informed consent form, taking into account the inclusion and exclusion criteria. Patients in two groups of 25 will be intervened with rice bran powder (15 grams per day equivalent to 1 tablespoon) and standard diet or standard diet alone (as a control group). The sampling method will be easy.

##### Participants/Inclusion and exclusion criteria

Patients with an age range of 20 to 70 years, Patients with metabolic syndrome, Do not use vitamin and mineral supplements, antioxidants, fiber supplements, omega 3, No history of kidney disease, kidney stones, gastrointestinal diseases, gallstones, and autoimmune diseases, Current consumption of alcohol

##### Intervention groups

Intervention group: Patients with metabolic syndrome will consume 15 grams of bran powder, which is equivalent to 1 tablespoon of bran powder prepared by Giltaz company, for 8 weeks, along with their lunch or salad with rice. Control group: Patients with metabolic syndrome will be prescribed only a standard diet for 8 weeks. According to the formula, a standard diet consisting of 55 Percent carbohydrates, 18 Percent

protein and 27 Percent fat will be provided to patients by a nutrition consultant.

##### Main outcome variables

Lipid Profiles (Triglycerides, Total Cholesterol, LDL-C and HDL-C) Apo A1 and Apo B100 fasting blood sugar CRP D-dimer

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20180205038626N11**

Registration date: **2021-11-27, 1400/09/06**

Registration timing: **registered\_while\_recruiting**

Last update: **2021-11-27, 1400/09/06**

Update count: **0**

##### Registration date

2021-11-27, 1400/09/06

##### Registrant information

##### Name

Zahra Ahmadnia

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 13 3361 8177

##### Email address

zahmadnia@gums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-11-22, 1400/09/01

##### Expected recruitment end date

2022-11-22, 1401/09/01

**Actual recruitment start date**

empty

**Actual recruitment end date**

empty

**Trial completion date**

empty

**Scientific title**

Evaluation of the effects of rice bran powder administration on cardiovascular risk factors in adult patients with metabolic syndrome: A Randomized Controlled Open Label Trial

**Public title**

Evaluation of the effects of rice bran powder administration on cardiovascular risk factors in adult patients with metabolic syndrome

**Purpose**

Prevention

**Inclusion/Exclusion criteria**

**Inclusion criteria:**

Patients with an age range of 20 to 70 years Patients with metabolic syndrome Do not use vitamin and mineral supplements, antioxidants, fiber supplements, omega 3 No history of kidney disease, kidney stones, gastrointestinal diseases, gallstones, and autoimmune diseases No current consumption of alcohol

**Exclusion criteria:**

Changes in the patient's treatment plan during the study Changing the type of effective drugs used factors studied Reluctance to continue the study or to cause any dissatisfaction with the taste of the powder or to participate in the study

**Age**

From **20 years** old to **70 years** old

**Gender**

Both

**Phase**

2

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **50**

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Sampling and randomization The clinical trial study of two parallel groups of open label will be classified by block random sampling method. At first, participants were classified into two classes according to age (20 to 45 years and between 45 to 70 years) and then each person was randomly assigned to the intervention or control group using 1: 4 random blocks. Took. In this method, each group will be assigned one of the letters A or B. The website will also be used for randomization. The list of codes obtained from this website will be provided to the researchers, and each referring patient who met the inclusion criteria and did not meet the inclusion criteria and was willing to participate in the study, first entered the desired age group and based on The assigned code A or B enters the design. For

concealment, in this study, random allocation concealment, which is the method used to execute a random sequence on the study participants, will be used in such a way that the assigned group is not known before the individual is assigned. In this way, using opaque envelopes sealed with a random sequence, in this method, each of the random sequences created is recorded on a card and the cards are placed inside the envelopes in order. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface. Finally, the lids of the letter envelopes are glued and placed inside a box, respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants into the study, one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description**

**Placebo**

Used

**Assignment**

Parallel

**Other design features**

**Secondary Ids**

empty

**Ethics committees**

1

**Ethics committee**

**Name of ethics committee**

Ethics committee of Guilan University of Medical Sciences

**Street address**

Technology & Research Vice-chancellor of University; Shahid Siadati St; Namjoo St., Rasht

**City**

Rasht

**Province**

Guilan

**Postal code**

41446-66949

**Approval date**

2021-11-10, 1400/08/19

**Ethics committee reference number**

IR.GUMS.REC.1400.388

**Health conditions studied**

1

**Description of health condition studied**

Metabolic syndrome

**ICD-10 code**

E88.81

**ICD-10 code description**

Metabolic syndrome

## Primary outcomes

### 1

#### Description

Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C)

#### Timepoint

At the beginning of the study and 8 weeks later

#### Method of measurement

BT2000 device

### 2

#### Description

Serum levels of Apo A1 and Apo B100

#### Timepoint

At the beginning of the study and 8 weeks later

#### Method of measurement

Nephrometric device

### 3

#### Description

Fasting blood sugar

#### Timepoint

At the beginning of the study and 8 weeks later

#### Method of measurement

BT2000 device

### 4

#### Description

CRP

#### Timepoint

At the beginning of the study and 8 weeks later

#### Method of measurement

BT2000 device

### 5

#### Description

D-dimer

#### Timepoint

At the beginning of the study and 8 weeks later

#### Method of measurement

ELISA device

## Secondary outcomes

### 1

#### Description

Mean systolic and diastolic blood pressure

#### Timepoint

At the beginning of the study and 8 weeks later

#### Method of measurement

Pressure indicator

### 2

#### Description

Body mass index

### Timepoint

At the beginning of the study and 8 weeks later

### Method of measurement

Centimeter and scales

### 3

#### Description

Waist

#### Timepoint

At the beginning of the study and 8 weeks later

#### Method of measurement

Centimeter

## Intervention groups

### 1

#### Description

Intervention group: Patients with metabolic syndrome will be given 15 grams of rice bran equivalent to 1 tablespoon of Giltaz daily for eight weeks.

#### Category

Prevention

### 2

#### Description

Control group: A standard diet will be prescribed for 8 weeks. According to a standard diet containing 55% carbohydrates, 18% protein and 27% fat, a nutrition consultant will provide patients with.

#### Category

Prevention

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Heshmat hospital

##### Full name of responsible person

Marjan Mahdavi Roshan

##### Street address

15 Khordad St., next to the Management and Planning Organization of Gilan Province, Dr. Heshmat Heart Training and Treatment Center

##### City

Rasht

##### Province

Guilan

##### Postal code

4193955588

##### Phone

+98 13 3361 8177

##### Email

gums.icrc@gmail.com

## Sponsors / Funding sources

## 1

### Sponsor

**Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

محمد رضا نقی پور

**Street address**

Technology & Research Vice-chancellor of University;  
Shahid Siadati St; Namjoo St., Rasht

**City**

Rasht

**Province**

Guilan

**Postal code**

41446-66949

**Phone**

+98 13 3333 5821

**Email**

naghi@gums.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Rasht University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Zahra ahmadnia

**Position**

Nurse

**Latest degree**

Master

**Other areas of specialty/work**

Nursery

**Street address**

Dr. Heshmat Hospital; Bayani St; Mosala Square;  
Rasht.

**City**

Rasht

**Province**

Guilan

**Postal code**

4193955588

**Phone**

+98 13 3361 8177

**Email**

zahmadnia@gums.ac.ir

### Person responsible for scientific inquiries

**Contact****Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Marjan Mahdavi Roshan

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

Dr. Heshmat Hospital; Bayani St; Mosala Square;  
Rasht.

**City**

rasht

**Province**

Guilan

**Postal code**

4193955588

**Phone**

+98 13 3361 8177

**Email**

Marjanmahdavi60@gmail.com

### Person responsible for updating data

**Contact****Name of organization / entity**

Rasht University of Medical Sciences

**Full name of responsible person**

Zahra ahmadnia

**Position**

Nurse

**Latest degree**

Master

**Other areas of specialty/work**

Nursery

**Street address**

Dr. Heshmat Hospital; Bayani St; Mosala Square;  
Rasht.

**City**

Rasht

**Province**

Guilan

**Postal code**

4193955588

**Phone**

+98 13 3361 8177

**Email**

gums.icrc@gmail.com

### Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to

make this available

**Title and more details about the data/document**

Information on the main outcome

**When the data will become available and for how long**

Access period starts 6 months after the results are published

**To whom data/document is available**

Researchers working in academic institutions

**Under which criteria data/document could be used**

Request to receive unidentifiable personal data or other documents

**From where data/document is obtainable**

Marjan Mahdavi Roshan

**What processes are involved for a request to access data/document**

By email to Dr.Marjan Mahdavi Roshan

**Comments**